NTT and Assuta Rise Join Forces to Revolutionize Medical AI Research
With the significant acceleration of Artificial Intelligence in the medical field, more and more startups and companies are inclined to improve and refine their solutions, from drug development to large-scale research. Taking medical AI one step further, NTT DATA’s research platform, Advocate AI, is designed to consolidate medical data from across the globe, providing a unified space that facilitates advanced medical research and AI model training from multiple global sources.
Assuta, the first Israeli healthcare organization to join Advocate AI, was initially chosen due to its proven record in the field of medical AI. Over the years, Assuta, through RISE, has collaborated with researchers and tech companies to push the boundaries of medical technology.
Daniel Rabina, Head of RISE, expressed enthusiasm for the partnership, saying, “Assuta is proud to continue leading the medical AI revolution in Israel and worldwide. The partnership with NTT will increase our involvement in the development processes of medical technologies, in collaboration with leading research and development bodies around the world. We’re excited to join NTT’s network and contribute to the future of medicine and the health of millions of patients. We see great importance in engaging in innovation and creating collaborations with leading entities like NTT, which bring continuous improvement in the quality of care and service we provide to patients.”
Part of Advocate AI’s cutting-edge technology is powered by the Israeli startup Rhino Health, which enables data to be analyzed without transferring it from its source. This means that institutions can participate in AI research without compromising data privacy, ensuring a more secure and ethical approach to medical innovation.
NTT Corporation, with over $100 billion in annual sales, continues to invest in Israel, fostering over 80 proof-of-concept projects with local startups. By merging Assuta’s clinical expertise with NTT’s technological strength, the two organizations are set to make significant strides in medical research, facilitating the development of new treatments, improved medical equipment, and enhanced AI models.
Lilach Denewitz, Director of Strategy and Partnerships at NTT Israel says, “We’re very excited about Assuta joining one of the world’s leading AI platforms in the medical field and encourage other Israeli healthcare organizations to join. The connection between Israeli healthcare institutions and NTT’s platform creates a perfect synergy: for Israeli institutions, the connection with NTT enables a global leap forward by introducing innovation to a giant company and from there to the rest of the world, as well as leveraging the Israeli market’s relative advantage in order to access global opportunities for developing medical technologies. For global research bodies, pharmaceutical companies, and medical startups, Israel is an ideal environment where the vast majority of medical information has been digitally recorded for several decades. Additionally, the ethnic diversity of Israel’s population makes it a microcosm for medical research, allowing for easier and more accurate development of global tools.”